Fiche du document
2013
- doi: 10.1038/nm.3109
- issn: 1078-8956
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1038/nm.3109
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/23475201
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1546-170X
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_F10C91F4362C5
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Sujets proches
Infectious diseasesCiter ce document
R.A. Cubas et al., « Inadequate T follicular cell help impairs B cell immunity during HIV infection. », Serveur académique Lausannois, ID : 10.1038/nm.3109
Métriques
Partage / Export
Résumé
The majority of HIV-infected individuals fail to produce protective antibodies and have diminished responses to new immunizations. We report here that even though there is an expansion of follicular helper T (TFH) cells in HIV-infected individuals, the cells are unable to provide adequate B cell help. We found a higher frequency of programmed cell death ligand 1 (PD-L1)(+) germinal center B cells from lymph nodes of HIV-infected individuals suggesting a potential role for PD-1-PD-L1 interaction in regulating TFH cell function. In fact, we show that engagement of PD-1 on TFH cells leads to a reduction in cell proliferation, activation, inducible T-cell co-stimulator (ICOS) expression and interleukin-21 (IL-21) cytokine secretion. Blocking PD-1 signaling enhances HIV-specific immunoglobulin production in vitro. We further show that at least part of this defect involves IL-21, as addition of this cytokine rescues antibody responses and plasma cell generation in vitro. Our results suggest that deregulation of TFH cell-mediated B cell help diminishes B cell responses during HIV infection and may be related to PD-1 triggering on TFH cells. These results demonstrate a role for TFH cell impairment in HIV pathogenesis and suggest that enhancing their function could have a major impact on the outcome and control of HIV infection, preventing future infections and improving immune responses to vaccinations.